QuiaPEG

Newsroom

Mar 12, 2018

QuiaPEG Pharmaceuticals Holding AB (publ), ”QuiaPEG”, announces today that, through its subsidiary, the company has entered into a licensing and commercialization agreement with the global Chinese company Xiamen SinoPEG Biotech Ltd, ”SinoPEG”, a key player in the pegylation industry for development , manufacturing, marketing and sales of products and services based on QuiaPEG’s release pegylation technology, Uni-Qleaver®.

Download press release (PDF)
Contact
QuiaPEG Pharmaceuticals Holding AB

Virdings Allé 32 B
754 50 Uppsala
Sweden
+46 (0) 70 693 12 53
info@quiapeg.com

User terms & privacy policy
Send a message